Analyst Rating On these Stocks: CenturyLink, Inc. (NYSE:CTL), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

0
203

CenturyLink, Inc. (NYSE:CTL):

Last Trade:

CenturyLink, Inc. (NYSE:CTL) ended its previous trading session at $20.97 with the Gain of 13.11%. The company’s market cap is $22.31 Billion, and the average volume is $8.9 Million. The 52-Week High range of the stock is $22.03, while the 52-week low range is $13.16. The Price to Sales (P/S) of the stock is 1.15, while P/B (Price to Book) stands at 0.95. When we look at the Volatility of the company, Week Volatility is at 2.96% whereas Month Volatility is at 2.30%.


For the ongoing Fiscal Quarter, 15 analysts have an average earnings forecast of $0.24 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $0.17, while the High earnings estimate is $0.37.Comparatively, EPS for the same quarter last year was $0.47.


According to 16 analysts, the Average Revenue Estimate for the current Fiscal quarter is $5.91 Billion and the Low Revenue estimate is $5.87 Billion, while the High Revenue estimate is $5.98 Billion.


CenturyLink, Inc. (NYSE:CTL) analysts on average have given a price target of $20.18 on CTL stock.


According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 2.6 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.


Ionis Pharmaceuticals, Inc. (NASDAQ:IONS):


Previous Trade:

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shares Jumped 5.79% and ended the day at $48.21. Its 52-week high and low range is between $65.51 and $39.07. The company’s outstanding shares are 124 Million. The volume of the company in the last trading session was 1.24 Million. The stock has a market cap of 5.98 Billion. The Stock shows P/E value of 63.6 and Forward P/E of 79.82.


According to Finviz reported data, The SMA20 of the stock is at 7.77%, SMA50 is 7.75 percent, while SMA200 is -1.03%. The stock is currently has its Return on Assets (ROA) value of -0.9 Percent. The Return on Investment and Return on Equity (ROE) values are 14.6 percent and -3.9 percent, respectively.


The company’s ATR (Average True Range) is 1.86. The Weekly Volatility is 5.47% and the Monthly Volatility is 3.89%.


When we look at the Analyst Recommendations of the stock, the company has 2.9 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.


Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) analysts on average have given a price target of $20.18 on IONS stock.


Ionis Pharmaceuticals, Inc.’s Average Earnings Estimate for the current quarter is $-0.03, according to consensus of 11 analysts. The low EPS estimate is $-0.37, while the high EPS estimate is $0.12.


Average Revenue Estimate of the company for the current Fiscal Quarter is $144.31 Million, according to consensus of 8 analysts. The higher end of the revenue estimate is $182.5 Million and the lower end is $100 Million.

SHARE